RGEN vs A vs TMO Stock Comparison

Repligen, Agilent Technologies and Thermo Fisher Scientific Prices as of Nov 13, 2026 Peers: Industry group
RGEN Repligen Corp
$167.79 -5.8% 1M +11.4% 1Y
Market cap
$9.16B
P/E
–
Revenue (TTM)
$805.61M
Div. yield
–
Life Sciences Tools Healthcare
2 wins
A Agilent Technologies, Inc.
$173.91 -0.1% 1M +18.4% 1Y
Market cap
$48.53B
P/E
33.7x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
6 wins

Head to Head

12 decided of 12

Agilent Technologies leads on 6 of the 12 questions below (Agilent Technologies 6, Thermo Fisher Scientific 4, Repligen 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRGENATMOLeader
Larger companyMarket capitalisation $9.16B $48.53B $254.02B TMO
Cheaper on earningsLower P/E, profitable companies only -775.9x 33.7x 35.9x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 86.0x 26.6x 27.0x A
Faster revenue growthRevenue growth, trailing twelve months +13.8% +8.6% +8.3% RGEN
More profitableNet margin, trailing twelve months -1.5% 19.5% 14.9% A
Better return on capitalReturn on invested capital 0.0% 13.1% 8.0% A
Less leveragedLower net debt / EBITDA -2.8x 1.1x 3.1x RGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.00% A
Better 1-year returnPrice return, last 12 months +11.4% +18.4% +20.7% TMO
Better 5-year returnAnnualised price return, 5 years -8.3%/yr +1.6%/yr +2.0%/yr TMO
Less volatileAnnualised volatility, 1 year 46.5% 32.8% 30.7% TMO
Higher overall scoreMean of the five percentile scores vs peers 58/100 61/100 60/100 A

Percentile Scorecard

RGENATMO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRGENATMO
Valuation 56 #108 of 243 60 #98 of 243 62 #94 of 243
Growth 30 #161 of 228 37 #144 of 228 41 #136 of 228
Profitability 67 #75 of 222 93 #17 of 222 82 #40 of 222
Financial Health 80 #50 of 248 53 #117 of 248 31 #172 of 248
Shareholder Returns 57 #68 of 158 64 #57 of 158 82 #29 of 158
Overall 58 61 60
  • RGEN ranked among 252 companies in Medical Devices and Diagnostics
  • A ranked among 252 companies in Medical Devices and Diagnostics
  • TMO ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRGENATMOSPY
1 month -5.8%-0.1%+4.0% -2.0%
3 months +0.6%+17.1%+19.1% -2.8%
6 months +63.1%+55.7%+59.7% +2.0%
Year to date +2.4%+27.8%+20.8% +10.6%
1 year +11.4%+18.4%+20.7% +12.2%
3 years +9.1%+55.8%+52.5% +68.1%
3 years, per year +2.9%+15.9%+15.1% +18.9%
5 years -35.1%+8.1%+10.2% +61.4%
5 years, per year -8.3%+1.6%+2.0% +10.1%
10 years +419.6%+275.0%+362.9% +248.5%
10 years, per year +17.9%+14.1%+16.6% +13.3%

Risk

MeasureRGENATMOSPY
Volatility, 1Y 46.5%32.8%30.7% 13.6%
Downside volatility, 1Y 47.4%28.1%29.2% 13.9%
Beta vs S&P 500, 1Y 1.210.910.71 1.00
Return / volatility, 1Y 0.250.560.67 0.90
Max drawdown, 5Y -64.7%-39.6%-41.5% -25.4%
From 52-week high -13.8%-4.2%-3.0% -3.2%
52-week high $194.57$181.54$721.63 $779.14
52-week low $102.87$110.24$438.34 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRGENATMO
P/E now vs peer median -804.0xmedian 26.5x 34.1xmedian 26.5x 36.6xmedian 26.5x
P/S now vs peer median 11.8xmedian 2.7x 6.7xmedian 2.7x 5.5xmedian 2.7x
EV/EBITDA now vs peer median 83.9xmedian 18.4x 26.8xmedian 18.4x 25.5xmedian 18.4x
P/FCF now vs peer median 89.1xmedian 25.4x 38.7xmedian 25.4x 34.2xmedian 25.4x
P/B now vs peer median 4.5xmedian 2.5x 6.7xmedian 2.5x 4.7xmedian 2.5x
PEG now vs peer median 28.28median 0.98 3.46median 0.98 4.84median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRGENATMO
Revenue $805.61M $7.37B $47.35B
Gross profit $430.67M $3.97B $19.45B
Operating income $18.24M $1.64B $8.47B
Net income -$11.80M $1.44B $7.09B
Free cash flow $106.72M $1.27B $7.60B
R&D $57.23M $485.00M $1.40B
EPS (diluted) $-0.21 $5.09 $19.06
Cash & equivalents $726.96M $1.76B $5.46B
Total debt $555.60M $3.95B $41.37B
Shares (diluted) 56.56M 283.00M 371.00M
Enterprise value $5.93B $41.42B $230.53B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRGENATMO
P/E -804.0x 34.1x 36.6x
P/FCF 89.1x 38.7x 34.2x
P/Operating cash flow 73.2x 30.5x 27.8x
P/S 11.8x 6.7x 5.5x
P/B 4.5x 6.7x 4.7x
P/Tangible book 5.3x 7.6x 7.1x
EV/EBITDA 83.9x 26.8x 25.5x
EV/EBIT 504.7x 31.3x 34.8x
EV/Revenue 11.4x 6.9x 6.2x
EV/FCF 86.3x 40.4x 38.8x
EV/Operating cash flow 70.9x 31.8x 31.6x
PEG (3Y EPS CAGR) 28.28 3.46 4.84

Growth

14 metrics
MetricRGENATMO
Revenue growth (1Y) 13.8% 8.6% 8.3%
Revenue CAGR (3Y) 7.3% 1.8% 2.9%
Gross profit growth (1Y) 33.0% 11.2% 7.8%
Gross profit CAGR (3Y) 13.3% 3.7% 4.0%
Operating income growth (1Y) 2,185% 13.5% 12.8%
Operating income CAGR (3Y) -40.5% 5.1% 7.2%
Net income growth (1Y) -779.2% 18.0% 7.9%
Net income CAGR (3Y) -28.4% 8.3% 6.2%
EPS growth (1Y) -778.9% 18.9% 9.7%
EPS CAGR (3Y) -28.4% 9.8% 7.6%
Operating cash flow growth (1Y) -0.8% 7.6% 21.9%
Operating cash flow CAGR (3Y) 5.3% -1.9% 4.5%
Free cash flow growth (1Y) -3.0% 16.5% 24.3%
Free cash flow CAGR (3Y) 17.6% -3.7% 5.1%

Profitability

14 metrics
MetricRGENATMO
Gross margin 53.5% 53.8% 41.1%
EBITDA margin 13.6% 25.9% 24.4%
Operating margin 2.3% 22.2% 17.9%
Pretax margin 1.0% 22.5% 16.7%
Net margin -1.5% 19.5% 14.9%
FCF margin 13.2% 17.2% 16.0%
Operating cash flow margin 16.1% 21.8% 19.7%
Return on equity -1.7% 19.9% 13.2%
Return on assets -1.2% 10.7% 6.2%
Return on invested capital 0.0% 13.1% 8.0%
Return on capital employed 0.6% 14.6% 8.5%
Asset turnover 0.3x 0.5x 0.4x
Cash conversion (OCF / net income) -11.0x 1.1x 1.3x
Stock comp / revenue 4.2% 1.8% 0.7%

Financial Health

11 metrics
MetricRGENATMO
Debt / assets 19.0% 28.3% 36.2%
Debt / equity 0.3x 0.5x 0.8x
Net debt / EBITDA -2.8x 1.1x 3.1x
Debt / FCF 5.2x 3.1x 5.4x
Liabilities / assets 28.5% 47.3% 52.1%
Equity / assets 71.5% 52.7% 47.9%
Interest coverage 0.8x 15.5x 12.0x
Current ratio 9.9x 2.1x 1.8x
Quick ratio 8.1x 1.4x 1.2x
Cash ratio 6.9x 0.8x 0.4x
Altman Z-score 7.80 5.77 4.18

Shareholder Returns

7 metrics
MetricRGENATMO
Dividend yield – 0.6% 0.3%
Net buyback yield -0.2% 0.6% 1.6%
Shareholder yield -0.2% 1.2% 1.8%
Payout ratio (earnings) – 19.9% 9.5%
Payout ratio (FCF) – 22.6% 8.9%
Dividend growth (1Y) – 2.1% 8.0%
Dividend CAGR (3Y) – 3.1% 10.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRGENATMO
Forward P/E 86.0xFY2026 26.6xFY2026 27.0xFY2026
EPS, next fiscal year $1.95FY2026 $6.54FY2026 $25.92FY2026
EPS growth, next FY +14.0%FY2026 +17.0%FY2026 +13.3%FY2026
EPS growth, the year after +29.2% +0.2% +2.2%
Revenue, next fiscal year $791.31MFY2026 $7.87BFY2026 $50.12BFY2026
Revenue growth, next FY +7.2%FY2026 +15.3%FY2026 +12.5%FY2026
Revenue growth, the year after +44.3% -5.6% -2.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRGENATMO
Held by institutions 100.0% 92.6% 90.2%
Institutions holding 483 1,126 2,627
Change in shares held, QoQ +1.2% +3.2% +0.8%
Institutions buying 273 601 1,145
Institutions selling 141 351 1,145
Buyers to sellers 1.94 1.71 1.00

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RGENATMO
RGEN 1.00 0.63 0.68
A 0.63 1.00 0.74
TMO 0.68 0.74 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RGEN, A and TMO?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Repligen (RGEN) $9.16B, Agilent Technologies (A) $48.53B, Thermo Fisher Scientific (TMO) $254.02B.

Which stock is cheaper, RGEN, A and TMO?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Repligen (RGEN) -775.9x, Agilent Technologies (A) 33.7x, Thermo Fisher Scientific (TMO) 35.9x). On next year's consensus earnings, Agilent Technologies (A) is cheapest (Repligen (RGEN) 86.0x, Agilent Technologies (A) 26.6x, Thermo Fisher Scientific (TMO) 27.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Repligen (RGEN) +13.8%, Agilent Technologies (A) +8.6%, Thermo Fisher Scientific (TMO) +8.3%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Repligen (RGEN) -1.5%, Agilent Technologies (A) 19.5%, Thermo Fisher Scientific (TMO) 14.9%). On return on invested capital, Agilent Technologies (A) leads (Repligen (RGEN) 0.0%, Agilent Technologies (A) 13.1%, Thermo Fisher Scientific (TMO) 8.0%).

Which stock has performed better?

Over the past year Thermo Fisher Scientific (TMO) returned the most: Repligen (RGEN) +11.4%, Agilent Technologies (A) +18.4%, Thermo Fisher Scientific (TMO) +20.7%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Repligen (RGEN) -8.3%/yr, Agilent Technologies (A) +1.6%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Agilent Technologies (A) has the highest dividend yield: Repligen (RGEN) 0.00%, Agilent Technologies (A) 0.01%, Thermo Fisher Scientific (TMO) 0.00%. Repligen (RGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Repligen (RGEN) 46.5%, Agilent Technologies (A) 32.8%, Thermo Fisher Scientific (TMO) 30.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RGEN, A and TMO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.